These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 36123537)

  • 1. Causes of polymyxin treatment failure and new derivatives to fill the gap.
    Chiu S; Hancock AM; Schofner BW; Sniezek KJ; Soto-Echevarria N; Leon G; Sivaloganathan DM; Wan X; Brynildsen MP
    J Antibiot (Tokyo); 2022 Nov; 75(11):593-609. PubMed ID: 36123537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin B: similarities to and differences from colistin (polymyxin E).
    Kwa A; Kasiakou SK; Tam VH; Falagas ME
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
    Ardebili A; Izanloo A; Rastegar M
    Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New polymyxin derivatives that display improved efficacy in animal infection models as compared to polymyxin B and colistin.
    Vaara M
    Med Res Rev; 2018 Sep; 38(5):1661-1673. PubMed ID: 29485690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.
    Nation RL; Li J; Cars O; Couet W; Dudley MN; Kaye KS; Mouton JW; Paterson DL; Tam VH; Theuretzbacher U; Tsuji BT; Turnidge JD
    Lancet Infect Dis; 2015 Feb; 15(2):225-34. PubMed ID: 25459221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel derivatives of polymyxins.
    Vaara M
    J Antimicrob Chemother; 2013 Jun; 68(6):1213-9. PubMed ID: 23412346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
    Domalaon R; Berry L; Tays Q; Zhanel GG; Schweizer F
    Bioorg Chem; 2018 Oct; 80():639-648. PubMed ID: 30053708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of polymyxin resistance through the food chain, the global crisis.
    Ray M; Manjunath A; Halami PM
    J Antibiot (Tokyo); 2022 Apr; 75(4):185-198. PubMed ID: 35079146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters.
    Kim SJ; Jo J; Kim J; Ko KS; Lee W
    Microbiol Spectr; 2024 Apr; 12(4):e0368723. PubMed ID: 38391225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical Role of Position 10 Residue in the Polymyxin Antimicrobial Activity.
    Patil NA; Ma W; Jiang X; He X; Yu HH; Wickremasinghe H; Wang J; Thompson PE; Velkov T; Roberts KD; Li J
    J Med Chem; 2023 Feb; 66(4):2865-2876. PubMed ID: 36745479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. History, Chemistry and Antibacterial Spectrum.
    Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
    Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational use of intravenous polymyxin B and colistin: A review.
    Zakuan ZD; Suresh K
    Med J Malaysia; 2018 Oct; 73(5):351-359. PubMed ID: 30350826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.
    Ezadi F; Ardebili A; Mirnejad R
    J Clin Microbiol; 2019 Apr; 57(4):. PubMed ID: 30541939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Polymyxin-Like Antibiotics.
    Velkov T; Roberts KD
    Adv Exp Med Biol; 2019; 1145():343-362. PubMed ID: 31364086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.
    Velkov T; Roberts KD; Nation RL; Thompson PE; Li J
    Future Microbiol; 2013 Jun; 8(6):711-24. PubMed ID: 23701329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep Mutational Scanning Reveals the Active-Site Sequence Requirements for the Colistin Antibiotic Resistance Enzyme MCR-1.
    Sun Z; Palzkill T
    mBio; 2021 Dec; 12(6):e0277621. PubMed ID: 34781730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of polymyxins to treat carbapenem resistant infections in neonates and children.
    Thomas R; Velaphi S; Ellis S; Walker AS; Standing JF; Heath P; Sharland M; Dona' D
    Expert Opin Pharmacother; 2019 Mar; 20(4):415-422. PubMed ID: 30576264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MCR-1 Inhibition with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Restores Sensitivity to Polymyxin in
    Daly SM; Sturge CR; Felder-Scott CF; Geller BL; Greenberg DE
    mBio; 2017 Nov; 8(6):. PubMed ID: 29114023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the arsenal for multidrug-resistant Acinetobacter infections: polymyxin antibiotics.
    Kassamali Z; Jain R; Danziger LH
    Int J Infect Dis; 2015 Jan; 30():125-32. PubMed ID: 25461655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.